Join us at the 2nd Donor Selection & Cell Source Summit - an unparalleled event dedicated to revolutionizing donor testing, screening, and cell source selection. This is your chance to […]

The landmark FDA approval of the first MASH therapeutic, the orphan drug designation for systemic sclerosis trials, and the rapid advancement of IPF treatments through clinical phases have ignited a […]

Mark your calendars for November because LEAP HR: Emerging Biopharma is back! Returning to Boston from November 19-20, this event is designed specifically for CHROs, CPOs, and Heads of HR […]

Join us at the inaugural Portfolio Strategy & Decision Making for Biopharma Summit - the must-attend event for pharma and biotech leaders seeking to sharpen their portfolio strategies in today’s […]

Liquid biopsies are revolutionizing clinical trials, emerging as a game-changing diagnostic tool for monitoring molecular residual disease and detecting disease resistance. This breakthrough enables precise patient stratification, ensuring they receive […]

As structural biology tools and screening technologies advance, the GPCR super family continues to be a hot area of drug discovery, with the potential to treat a plethora of diseases. […]

The 2nd Cell Therapy for Autoimmune Disease Summit returns to Philadelphia bigger and better after last year’s explosive debut as the only meeting covering every aspect of bringing cell therapies to the autoimmune space. This year’s […]

As the field of cell therapy evolves, integrating the latest technologies and robust analytical methods has never been more crucial. Join us at the 6th Cell Therapy Analytical Development Summit […]

The Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer Vaccine Summit) returns to Boston bringing together the top industry players developing individualized approaches across several modalities including mRNA, […]

Just 11 years after Emmanuelle Charpentier and Jennifer Doudna’s seminal CRISPR discovery, Casgevy marks the first approved gene-editing therapy, a major milestone for the field. This breakthrough signals the beginning […]

Discover & Develop Selective, Clinically Validated & Novel Covalent Therapeutics to Expand the Targetable Proteome & Non-Cystine Amino Acid Space in Oncology, Immunology & Beyond The covalency renaissance continues as […]

With recent accelerated approval wins, positive clinical trial readouts, progression through clinical pipelines and exciting mergers and acquisitions, it has certainly been an industry-defining year for the rare and genetic […]

With Remix Therapeutics joining forces with Roche and Daiichi Sankyo partnering with Depixus, there have been many valuable collaborations entering the RNA-targeting field, accelerating efficacious and selective small molecules targeting […]

With the community hailing the latest FDA-approved therapeutic with Novartis’ inhibitor of the alternative complement for PNH, which inhibitor will be the next to harness the complement system for the […]

The 4th ADC Target Selection Summit returns to outline approaches to identify and validate novel targets that can be clinically and commercially successful and discuss rationale behind selecting a target […]

Join industry leaders like Eli Lilly, Merck, Novo Nordisk and Pfizer at the 4th Applied Biocatalysis & Enzyme Engineering Summit (December 10-12, 2024 – Philadelphia, PA). This is your perfect moment to […]

Join 100+ leading PAT scientists, engineers, process development, CMC, MSAT and quality experts at the 3rd Annual PAT & Real Time Quality Summit. Explore cutting-edge data-driven case studies, engage in dynamic roundtables and deep dive into […]

Integrating Expertise from Software Development, Quality Assurance, Regulatory Affairs, & Product Teams to Drive Innovation in Alignment with Global Regulatory Guidelines, AI & ML Enabled Software, Cybersecurity, & Agile Methodologies: […]

The 4th mRNA-Based Therapeutics Summit Europe returns to Frankfurt, Germany as the industry’s premier forum dedicated to showcasing the hottest disease targets, never-before-seen pre-clinical and clinical data, and demonstrating key routes to commercial success for […]

RNAi Therapeutics holds more promise than ever in treating many diseases beyond the liver, with momentum in this field growing stronger than ever. Breakthrough companies such as Argonaute RNA and […]

The 3rd Molecular Glue Drug Development Summit is returning to bring together leaders across biopharma covering the depth and breadth of the molecular glue field from rational discovery to improving […]

Fresh from the reapproval of Roche/Genentech’s Susvimo, positive readouts for sustained release implants, and suprachoroidal delivery revolutionizing gene therapy delivery to the retina, matching the right delivery route to the […]

Waves of new models are being validated. A wider industry shift to precision oncology is requiring more specific genetic models. Availability and cost-effectiveness of sequencing and computational tools are enabling […]

Significant breakthroughs in CNS biology, coupled with innovative neuroscience technologies and a more supportive regulatory landscape, have fueled increased investment and pharmaceutical interest in the CNS. With AbbVie, BMS, and […]

In recent industry news, AAV gene therapies are gaining momentum, with groundbreaking achievements like RegenxBio’s RGX-121 trial for Hunter syndrome, demonstrating significant improvements in neurodevelopmental skills. The global AAV therapy […]

Advancing Curative Therapies for Autoimmune Diseases  Building on the success of last year’s meeting, the 8th Antigen-Specific Immune Tolerance Summit will bring together 120+ end-to-end experts in immune tolerance for autoimmune diseases. […]

Investors in the cell therapy industry are actively looking into solid tumours, autoimmune indications and novel engineering as the best place to allocate their money and resources. This, along with […]

4th mRNA Analytical Development & Quality Control Summit | February 25-27, 2025 Excitement for mRNA therapeutics continues, as RNA technologies are awarded the Nobel Prize for the second year running. […]

The radiopharmaceutical race is on and pharma leaders such as AstraZenca, BMS , Eli Lilly, Novartis and Sanofi are not getting left behind. Bolstering discovery pipelines through acquisitions of preclinical […]

2025 is shaping up to be the ‘bounce back’ year for natural killer therapy. For the first time we are seeing efficacious in-patient data, expansion into autoimmune disease, and combination […]